GlassScriptPhysician profile
Brian D Salmenson
NPI 1255335923
$2,360.62
in general payments reported to CMS, 2019-2025
19 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $251 · 2021: $331 · 2022: $104 · 2023: $583 · 2024: $491 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.52 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Glaukos Corporation | $384.62 | 2023-2024 | |
| Biotissue Holdings INC. | $175.21 | 2023 | |
| Novartis Pharmaceuticals Corporation | $159.08 | 2019-2021 | |
| Allergan, INC. | $125.86 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $121.09 | 2020 | |
| Rxsight INC | $100.59 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Alcon Vision LLC | $98.42 | 2024-2025 | Rocklatan, Tryptyr, Rhopressa |
| Kala Pharmaceuticals, INC. | $97.79 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $92.11 | 2019-2021 | |
| Oyster Point Pharma, INC. | $88.87 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $68.04 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $34.43 | 2021 | |
| Sight Sciences, INC. | $33.34 | 2021-2023 | Tearcare System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.93 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $28.20 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $22.57 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $20.95 | 2025 | Xdemvy |
| Eyepoint US, INC. | $17.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Salmenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.